CD47 and cancer: Similar treatment with CD47 blocking antibody InhibRx, as the ‘benchmark’ innate immune checkpoint, did trigger a clear increase in phagocytosis compared to untreated conditions, but the number of macrophages with engulfed cancer cells and the number of cancer cells per macrophage were lower than upon CD24 antibody treatment (Figure 2B, right panel).